Drug therapy of dementia in elderly patients. A review.

Abstract

Today drug therapy of dementia in elderly patients is possible. Owing to a huge increase in the number of elderly people throughout the Western world in the coming years, evidence-based treatment of dementia in this group is needed. The article reviews double-blind, randomized trials on the effect in dementia of donepezil, galantamine, rivastigmine and memantine up to 2003. A total of 27 studies were included. Donepezil, galantamine, rivastigmine and memantine improve cognition and the global level of functioning in mild to moderate Alzheimer's disease (AD). Most evidence exists for donepezil and galantamine. The effect of rivastigmine is best documented in Lewy body dementia (LB). Galantamine, memantine and donepezil may improve cognition in vascular dementia (VD). Galantamine may improve behavioural psychological symptoms of dementia (BPSD). No solid evidence for drug therapy in severe dementia exists. Elderly patients with mild to moderate AD should be offered drug therapy. One should also consider expanding the indication of dementia treatment to LB and VD. An international consensus on what primary efficacy variables to use is needed.

• Authors: Carsten Emil Olsen, Henrik Day Poulsen, Henrik K F Lublin
• Journal: Nordic journal of psychiatry (Nord J Psychiatry) Vol. 59 Issue 2 Pg. 71-7 ( 2005) ISSN: 0803-9488 [Print] England
• PMID: 16195103 (Publication Type: Journal Article, Review)

Chemical References

• Indans
• Neuroprotective Agents
• Phenylcarbamates
• Piperidines
• Galantamine
• Donepezil
• Rivastigmine
• Memantine

Topics

• Aged
• Alzheimer Disease (drug therapy)
• Dementia (drug therapy)
• Donepezil
• Galantamine (therapeutic use)
• Humans
• Indans (therapeutic use)
• Memantine (therapeutic use)
• Neuroprotective Agents (therapeutic use)
• Phenylcarbamates (therapeutic use)
• Piperidines (therapeutic use)
• Randomized Controlled Trials as Topic
• Rivastigmine